Randomized, phase 3 trial of inotuzumab ozogamicin plus rituximab (R-InO) versus chemotherapy for relapsed/refractory aggressive B-cell non-Hodgkin lymphoma (B-NHL).

被引：7
|
作者：
Dang, Nam H.
Ogura, Michinori
Castaigne, Sylvie
Fayad, Luis
Jerkeman, Mats
Radford, John A.
Pezzutto, Antonio
Bondarenko, Igor
Stewart, Douglas Allan
Shnaidman, Michael
Sullivan, Sharon
Vandendries, Erik
Tobinai, Kensei
Ramchandren, Rod
Hamlin, Paul A.
Gine, Eva
Ando, Kiyoshi
机构：
[1] Univ Florida, Gainesville, FL USA
[2] Nagoya Daini Red Cross Hosp, Nagoya, Aichi, Japan
[3] Hosp Versailles, Versailles, France
[4] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma & Myeloma, Houston, TX 77030 USA
[5] Skane Univ Hosp, Lund, Sweden
[6] Univ Manchester, Christie Hosp NHS Fdn Trust, Manchester, Lancs, England
[7] Charite, Dept Hematol Oncol & Tumor Immunol, D-13353 Berlin, Germany
[8] Municipal Clin Hosp 4, State Med Acad, Dnepropetrovsk, Ukraine
[9] Univ Calgary, Tom Baker Canc Ctr, Calgary, AB, Canada
[10] Pfizer Inc, New York, NY USA
[11] Pfizer, Cambridge, MA USA
[12] Pfizer Inc, Cambridge, MA USA
[13] Natl Canc Ctr, Tokyo, Japan
[14] Wayne State Univ, Karmanos Canc Inst, Detroit, MI USA
[15] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
[16] Hosp Quiron Barcelona, Inst Oncol Baselga, Unidad Hematol, Barcelona, Spain
[17] Tokai Univ, Sch Med, Univ Hosp, Hiratsuka, Kanagawa 25912, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 15期
关键词：
D O I：
10.1200/jco.2014.32.15_suppl.8529
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8529
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Chromosomal Alterations in Gene Expression-Defined Pediatric Aggressive B-Cell Non-Hodgkin Lymphoma (B-NHL)
    Deffenbacher, Karen E.
    Iqbal, Javeed
    Liu, Zhongfeng
    Perkins, Sherrie L.
    Lim, Megan S.
    Fu, Kai
    Shen, Yulei
    Staudt, Louis M.
    Rimsza, Lisa M.
    Jaffe, Elaine S.
    Rosenwald, Andreas
    Ott, German
    Delabie, Jan
    Campo, Elias
    Gascoyne, Randy D.
    Weisenburger, Dennis D.
    Greiner, Timothy C.
    Gross, Thomas
    Chan, Wing C.
    BLOOD, 2009, 114 (22) : 1142 - 1142
  • [32] A phase I trial of inotuzumab ozogamicin in combination with temsirolimus in patients with relapsed or refractory CD22-positive B-cell non-Hodgkin lymphomas
    Pirosa, Maria C.
    Zhang, Lu
    Hitz, Felicitas
    Novak, Urban
    Hess, Dagmar
    Terrot, Tatiana
    Pascale, Mariarosa
    Mazzucchelli, Luca
    Bertoni, Francesco
    Cavalli, Franco
    Zucca, Emanuele
    Stathis, Anastasios
    LEUKEMIA & LYMPHOMA, 2022, 63 (01) : 117 - 123
  • [33] Results from a phase I trial of pembrolizumab plus vorinostat in relapsed/refractory B-cell non-Hodgkin lymphoma
    Godfrey, James
    Mei, Matthew
    Chen, Lu
    Song, Joo Y.
    Bedell, Victoria
    Budde, L. Elizabeth
    Armenian, Saro
    Puverel, Sandrine
    Nikolaenko, Liana
    Chen, Robert
    Daniels, Shari
    Kennedy, Neena
    Peters, Lacolle
    Rosen, Steven T.
    Forman, Stephen J.
    Popplewell, Leslie L.
    Kwak, Larry W.
    Herrera, Alex F.
    REVISTA CHILENA DE LITERATURA, 2024, (109): : 533 - 542
  • [34] Results from a phase I trial of pembrolizumab plus vorinostat in relapsed/refractory B-cell non-Hodgkin lymphoma
    Godfrey, James
    Mei, Matthew
    Chen, Lu
    Song, Joo Y.
    Bedell, Victoria
    Budde, L. Elizabeth
    Armenian, Saro
    Puverel, Sandrine
    Nikolaenko, Liana
    Chen, Robert
    Daniels, Shari
    Kennedy, Neena
    Peters, Lacolle
    Rosen, Steven T.
    Forman, Stephen J.
    Popplewell, Leslie L.
    Kwak, Larry W.
    Herrera, Alex F.
    HAEMATOLOGICA, 2024, 109 (02) : 533 - 542
  • [35] Phase 3 trial of pixantrone plus rituximab versus gemcitabine plus rituximab in treating relapsed/refractory transplant-ineligible aggressive non-Hodgkin's lymphoma
    Georgiev, P. G.
    Belada, D.
    Dakhil, S.
    Inhorn, L. F.
    Andorsky, D.
    Liberati, A. M.
    Beck, J. T.
    Quick, D.
    Patti, C.
    Sivcheva, L.
    Zaucha, J. M.
    Pettengell, R.
    Devries, T.
    Dean, J. P.
    Pavlyuk, M.
    Failloux, N.
    Huebel, K.
    ANNALS OF ONCOLOGY, 2016, 27
  • [36] A phase I trial of dose-adjusted EPOCH plus inotuzumab ozogamicin (InO) in adults with relapsed/refractory (R/R) B lymphoblastic leukemia/lymphoma (B-ALL).
    Kopmar, Noam Edward
    Quach, Kim
    Gooley, Ted
    Martino, Christen
    Cherian, Sindhu
    Percival, Mary-Elizabeth M.
    Halpern, Anna B.
    Ghiuzeli, Cristina Maria
    Oehler, Vivian G.
    Abkowitz, Janis
    Walter, Roland B.
    Estey, Elihu
    Cassaday, Ryan Daniel
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [37] A pilot study of combined therapy with rituximab (R) and epoch in refractory or relapsed diffuse large B-cell Non-Hodgkin's Lymphoma (NHL).
    Aung, S
    Krishnan, J
    Lessin, L
    Priebat, D
    Sharma, D
    Malkovska, V
    BLOOD, 1999, 94 (10) : 257B - 257B
  • [38] A Phase I/II Trial of Combination Gemcitabine and Bortezomib (VEL-CADE®) for Relapsed/Refractory T-Cell Non-Hodgkin Lymphoma (NHL) and Aggressive B-Cell NHL
    Evens, Andrew M.
    Rosen, Steven T.
    Gordon, Leo I.
    Helenowski, Irene
    Kline, Justin
    Larsen, Annette
    Winter, Jane N.
    Smith, Sonali M.
    Van Besien, Koen M.
    BLOOD, 2011, 118 (21) : 715 - 716
  • [39] A phase II trial of Rituximab plus ESHAP as salvage chemotherapy in relapsed/refractory aggressive histology non-Hodgkin's lymphoma.
    Piliotis, EG
    Mangel, J
    Buckstein, R
    Imrie, K
    Spaner, D
    Reis, M
    Foden, C
    Boudreau, A
    Richardson, P
    Richardson, J
    Berinstein, N
    BLOOD, 2003, 102 (11) : 288B - 288B
  • [40] Final analysis of a randomized, phase III, trial using etoposide and G-CSF with or without rituximab (R) for peripheral stem cell mobilization (PSC) in B-cell non-Hodgkin lymphoma (B-NHL).
    Pohlman, B
    Rybicki, L
    Kuczkowski, E
    Brown, S
    Kalaycio, M
    Sobecks, R
    Andresen, S
    Bolwell, BJ
    BLOOD, 2005, 106 (11) : 91A - 92A
12345